Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine

GlaxoSmithKline632 enrolled

Overview

To evaluate the persistence of antibodies against hepatitis B, approximately 5 to 6 years after the first dose of the hepatitis B in the primary vaccination study.

All subjects who participated in the primary vaccination study, where subjects who received GSK Biologicals' hepatitis B vaccine and who will consent to participate in this long-term follow-up study, approximately 5 to 6 years after the primary vaccination study. The study will be conducted in only 3 centres out of the 4 centres in the primary vaccination study.

Study Type

INTERVENTIONAL

Enrollment

632

Conditions

Hepatitis B

Interventions

Hepatitis B vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects should have participated in the primary study and should have received the first primary dose of vaccination more than five years ago and less than six years ago before blood sampling in this long-term follow-up study. * Written informed consent obtained from the subject for the long-term follow-up.

Locations (3)

GSK Investigational Site

Wilrijk, Belgium

GSK Investigational Site

Munich, Bavaria, Germany

GSK Investigational Site

Basel, Switzerland

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.